A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and levnatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009)

  • Alamgeer, Muhammad (Primary Chief Investigator (PCI))
  • Day, Daphne (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date28/08/20 → 27/08/25

Keywords

  • phase 2 study
  • clinical trial
  • treatment safety
  • treatment efficacy
  • head and neck cancer